Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...

The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

Halozyme Therapeutics has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio and its subcutaneous injection platform. The ...

At the 2026 European Lung Cancer Congress (ELCC), Dr Nicolas Girard discussed updated data from the PALOMA-2 study, which ...